Real world analysis of the efficacy and safety of eribulin compared to utidelone in combination with capecitabine for the treatment of metastatic breast cancer
Cancer Cell International · 19.12.2024 · 24 (1)
DOI: 10.1186/s12935-024-03608-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Cell International, online erschienen am 19.12.2024. Verfasst von Mengya Feng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, The People's Hospital of Chuxiong Yi Autonomous Prefecture, No. 318 Lucheng South Road, Chuxiong, 675000, Yunnan, China. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Science and Technology Project of Yunnan Provincial Science and Technology Department, National Natural Science Foundation of China, Beijing Science And Technology Innovation Medical Development Foundation.
Abstract (Originalsprache)
BACKGROUND: The objective of this study was to compare the efficacy and safety of subsequent chemotherapy with single eribulin or utidelone combined with a capecitabine regimen in patients with advanced breast cancer who had previously been treated with anthracyclines and paclitaxel. METHODS: This work was a retrospective analysis of 85 patients from July 2018 to July 2023. Forty-two and 43 patients were treated with the eribulin regimen and the utidelone/capecitabine regimen, respectively. The endpoints included progression-free survival, overall survival, the objective remission rate and safety. Survival analyses and multifactorial analyses were performed via the Kaplan‒Meier method, log-rank test and Cox regression models. RESULTS: As of 15 April 2024, the mPFS durations of the patients in the utidelone/capecitabine and eribulin treatment groups were 7.7 and 5.2 months, respectively, and the mOS durations were 22.0 and 18.2 months, respectively. Subgroup analyses revealed that in advanced first-line therapy, the mPFS durations of the utidelone/capecitabine group and the eribulin group were 11.8 and 7.0 months, respectively, and this difference was significant. In the eribulin treatment arm, the mPFS of first-line therapy was 7.0, whereas it was 3.3 months for posterior-line therapy, and this difference was significant. The most common adverse reactions were neurotoxicity, hand‒foot syndrome, hematological toxicity, gastrointestinal toxicity, and abnormalities in hepatic and renal functions. CONCLUSIONS: In conclusion, either utidelone/capecitabine or eribulin chemotherapy may result in a survival benefit with a tolerable adverse effect profile and favorable safety profile in patients with metastatic breast cancer. The first-line use of eribulin resulted in better PFS and ORR than posterior-line use, and the combination of utidelone/capecitabine represents a more efficacious approach in the advanced first-line therapy of breast cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Breast Surgery, The People's Hospital of Chuxiong Yi Autonomous Prefecture, No. 318 Lucheng South Road, Chuxiong, 675000, Yunnan, China.
- Department of Oncology, The People's Hospital of Lincang, No.116 Nantang Street, Linxiang District, Lincang, 677000, Yunnan, China.
- Department II of General Surgery, The People's Hospital of Chuxiong Yi Autonomous Prefecture, No. 318 Lucheng South Road, Chuxiong, 675000, Yunnan, China.
- Department of Breast Surgery, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, No. 519 Kunzhou Road, Xishan District, Kunming, 650100, Yunnan, China.
- Department of Breast Surgery, The People's Hospital of Chuxiong Yi Autonomous Prefecture, No. 318 Lucheng South Road, Chuxiong, 675000, Yunnan, China. 646324947@qq.com.
- Department of Breast Surgery, The People's Hospital of Chuxiong Yi Autonomous Prefecture, No. 318 Lucheng South Road, Chuxiong, 675000, Yunnan, China. 1208253790@qq.com.
Förderung
- Science and Technology Project of Yunnan Provincial Science and Technology Department
- National Natural Science Foundation of China
- Beijing Science And Technology Innovation Medical Development Foundation
- Wu Jieping Medical Foundation
- Yunnan Health Training Project of High Level Talents
- Yunnan Province "14th Five-Year Plan" Provincial Key Clinical Specialty General Surgery Construction Project
Zitieren
APA
Feng, M., Bi, P., Kang, Y., Yang, D., Ren, S., Lu, X., Xie, G., Lei, H., & Mo, D. (2024). Real world analysis of the efficacy and safety of eribulin compared to utidelone in combination with capecitabine for the treatment of metastatic breast cancer. Cancer Cell International, 24(1). https://doi.org/10.1186/s12935-024-03608-7
Vancouver
Feng M, Bi P, Kang Y, Yang D, Ren S, Lu X, et al. Real world analysis of the efficacy and safety of eribulin compared to utidelone in combination with capecitabine for the treatment of metastatic breast cancer. Cancer Cell International. 2024;24(1). doi:10.1186/s12935-024-03608-7
BibTeX
@article{Feng2024,
author = {Feng, Mengya and Bi, Pingping and Kang, Yihua and Yang, Dechun and Ren, Shengnan and Lu, Xianping and Xie, Guojian and Lei, Hai and Mo, Dan},
title = {Real world analysis of the efficacy and safety of eribulin compared to utidelone in combination with capecitabine for the treatment of metastatic breast cancer},
journal = {Cancer Cell International},
year = {2024},
volume = {24},
number = {1},
doi = {10.1186/s12935-024-03608-7}
}
EUVIMED